Table 2.
Baseline characteristics.
| Non-inflamed rectal stump n = 37 [18.1%] | Inflamed rectal stump n = 167 [81.9%] | p-value | |||
|---|---|---|---|---|---|
| Sex [M] | 20 | 54.1 | 92 | 55.1 | 0.909 |
| Age at IPAA surgery [years], mean SD | 35.6 | 11.9 | 38.0 | 11.9 | 0.782 |
| Time of IPAA surgery | 0.461 | ||||
| 1999–2010 | 12 | 32.4 | 65 | 38.9 | |
| 2010–2017 | 25 | 67.6 | 102 | 61.1 | |
| Time between STC and IPAA [months], mean SD | 23.9 | 35.7 | 19.8 | 26.3 | 0.100 |
| BMI [kg/m2], mean SD | 26.3 | 5.4 | 23.7 | 3.9 | 0.136 |
| Diagnosis | 0.498 | ||||
| UC | 33 | 89.2 | 155 | 92.8 | |
| IBDU | 4 | 10.8 | 12 | 7.2 | |
| PSC | 2 | 5.4 | 3 | 1.8 | 0.224 |
| ASA | >0.99 | ||||
| I-II | 35 | 97.2 | 161 | 96.4 | |
| III-IV-V | 1 | 2.8 | 6 | 3.6 | |
| Smoking | 0.490 | ||||
| No | 26 | 78.8 | 106 | 66.3 | |
| Previously | 3 | 9.1 | 41 | 25.6 | |
| Yes | 4 | 12.1 | 13 | 8.1 | |
| Complications after STC | 6 | 16.2 | 36 | 21.5 | 0.578 |
| Unknown [STC other centre without clear rapport] | 9 | 24.3 | 31 | 18.6 | |
| UC left-sided | 9 | 24.3 | 49 | 29.3 | 0.428 |
| UC right-sided | 3 | 8.1 | 5 | 3.0 | |
| Pancolitis | 11 | 29.7 | 57 | 34.1 | |
| Toxic megacolon | 7 | 18.9 | 25 | 15.0 | |
| Unknown [preoperative scopy at other centre not received] | 7 | 18.9 | 31 | 18.6 | |
| Rectal stump therapy before IPAA [<12 weeks] | 4 | 11.4 | 30 | 18.1 | 0.459 |
| Steroid suppositories/enema useage | 2 | 5.7 | 18 | 10.8 | |
| Mesalazine suppositories/enema usage | 2 | 5.7 | 12 | 7.2 | |
| Systemic steroid useage before IPAA [<12 weeks, >20 mg/day] | 0 | 0.0 | 12 | 7.2 | 0.132 |
| Other systemic medication before IPAA <12 weeks]a | 0.547 | ||||
| None | 35 | 97.2 | 146 | 87.4 | |
| Mesalazine | 1 | 2.8 | 10 | 6.0 | |
| Thioprine | 0 | 0.0 | 4 | 2.4 | |
| Anti-TNF | 0 | 0.0 | 7 | 4.2 | |
| Pouch procedure | 0.467 | ||||
| Open | 16 | 43.2 | 79 | 47.6 | |
| Hand-assisted laparoscopic | 10 | 27.0 | 53 | 31.9 | |
| Total laparoscopic | 11 | 29.7 | 34 | 20.5 | |
| Stage of pouch procedure | 0.716 | ||||
| Modified two-stage | 31 | 83.8 | 133 | 79.6 | |
| Three-stage | 6 | 16.2 | 34 | 20.4 |
ASA, American Society of Anesthesiologists; UC, ulcerative colitis; IBDU, inflammatory bowel disease unclassified; STC, subtotal colectomy; M, male; IPAA, ileal pouch-anal anastomosis; SD, standard deviation; BMI, body mass index; PSC, primary sclerosing cholangitis; TNF, tumour necrosis factor.
aImmunosuppressive drug useage was defined as such when patients used steroids, immunomodulators (azathioprine [AZA], 6-mercaptopurine [6MP], and methotrexate [MTX]), or anti-tumour necrosis factor-alpha [anti-TNF] within 12 weeks preceding IPAA, considering the anti-TNF half-life.24 In case of steroids, patients had to use more than 20 mg/day.25